Visit a quote page and your recently viewed tickers will be displayed here. Shares of South San Francisco, Calif. The company said recent interactions with the European Medicine Agency suggested that the regulatory body was likely to adopt a negative opinion of the drug vosaroxin for the treatment of a type of leukemia in patients who were 60 years or older.

Sunesis said it was reducing resources for its leukemia research and shifting them to other areas. Earnings were in focus this week with companies like Amgen AMGN , Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days. Sunesis Pharmaceuticals' SNSS CEO Dan Swisher on Q1 Results - Earnings Call Transcript.

Biotech Forum Daily Digest: Spotlight On Heron Therapeutics. Sunesis Pharmaceuticals SNSS Presents At 16th Annual Needham Healthcare Conference - Slideshow. The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug. Sunesis Pharmaceuticals Reports First Quarter Financial Results and Recent Highlights. Lundin Law PC Announces an Investigation ofSunesis Pharmaceuticals, Inc.

Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin. Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS at AACR Annual Meeting.

Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia.

The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, and is headquartered in South San Francisco, CA.

By using this site you agree to the Terms of Service , Privacy Policy , and Cookie Policy. Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information.

All quotes are in local exchange time. Real-time last sale data for U. Intraday data delayed at least 15 minutes or per exchange requirements.

Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.

US Europe Asia FX Rates Futures Range 1D 5D 1M 3M 6M 1Y 2Y FTSE 7, Latest News All Times Eastern. Dow Jones Newswires 5: Time for IMF, eurozone to agree on a real solution for Greek debt crisis 5: Home Investing Quotes Stocks United States SNSS Overview Compare Quotes Stock Screener Earnings Calendar Sectors Nasdaq. Watch list Create SNSS Alert. Jun 21, 4: Advanced Charting 1D 5D 1M 3M 6M YTD 1Y 3Y All.

Customize MarketWatch Have Watchlists?

Log in to see them here or sign up to get started. Create Account … or Log In. No Items in Watchlist There are currently no items in this Watchlist. Add Ticker to Watchlist. Go to Your Watchlist. No Saved Watchlists Create a list of the investments you want to track. Create Watchlist …or try this starter list. Uh oh Something went wrong while loading Watchlist. No Recent Tickers Visit a quote page and your recently viewed tickers will be displayed here. Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.

Performance 5 Day 3. Recent News MarketWatch Other Dow Jones Sunesis shares drop as biotech drops leukemia drug marketing application Sunesis Pharmaceuticals Inc. ET by Wallace Witkowski. ET by Tomi Kilgore. Sunesis Pharmaceuticals downgraded to hold from buy at Cantor Fitzgerald Jul.

Ken Griffin has loaded up on Angie's List Oct. ET by Meena Krishnamsetty. United Rentals, Best Buy, GM lead the way lower Oct. ET by Ben Eisen. ET by Anora Mahmudova. A one-day fling for stocks, and fret more over gold than over the dollar Oct.

ET by Barbara Kollmeyer. Sunesis Pharma shares crater after failed cancer drug trial Oct. ET by Ciara Linnane. Sunesis Pharma says cancer drug railed in late-stage trial Oct.

SNSS Stock Price - Sunesis Pharmaceuticals Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Stocks to Watch Friday: ET by David B. Stocks to Watch Wednesday: ET by Steve Gelsi. ASCO studies shake up drug stocks Jun. ET by Val Brickates Kennedy. Exelixis, Sunesis lead drug stocks lower Jun. Twitter, FedEx, Pfizer Jun. ET on The Wall Street Journal.

Three Biotechs Ready to Partner Up Sep. Herbalife, Health Management, Potash Jul. For Stocks, Next Stop All-Time Highs? Apple Doesn't Matter as Much as You Think Sep.

WSB Holdings, United Natural Foods, Navidea Biopharma Sep. Recent News Other News Press Releases Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update Earnings were in focus this week with companies like Amgen AMGN , Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split Nasdaq:SNSS

Sunesis Pharmaceuticals' SNSS CEO Dan Swisher on Q1 Results - Earnings Call Transcript Sunesis Pharmaceuticals' SNSS CEO Dan Swisher on Q1 Results - Earnings Call Transcript May. ET on Seeking Alpha. Spotlight On Heron Therapeutics Biotech Forum Daily Digest: Spotlight On Heron Therapeutics May.

Sunesis Pharmaceuticals SNSS Presents At 16th Annual Needham Healthcare Conference - Slideshow Sunesis Pharmaceuticals SNSS Presents At 16th Annual Needham Healthcare Conference - Slideshow Apr.

Sunesis Pharmaceuticals, Inc. (SNSS) Option Chain - Stock Puts & Calls - obupexeh.web.fc2.com

Sunesis submits Day responses to CHMP regarding vosaroxin application; European launch expected in H2 Mar. Endocyte ECYT Reports Wider-than-Expected Loss in Q4 Mar. Alexion's sBLA for Soliris Receives FDA Acknowledgement Mar. Perrigo Launches First to Market OTC Equivalent of Rogaine Mar. Sunesis Pharmaceuticals' SNSS CEO Daniel Swisher on Q4 Results - Earnings Call Transcript Mar.

Spectrum SPPI Q4 Loss Narrower than Expected, Sales Beat Mar. Valeant VRX Issues Notes, Restructures Debt; Shares Down Mar. FDA Lifts Hold on Trial of AML Drug Mar. Ionis Pharma Lipid Disorder Candidate Positive in Phase III Mar.

SNSS Option Chain | Sunesis Pharmaceuticals, Inc. Stock - Yahoo Finance

GlaxoSmithKline's Nucala Positive in Label Expansion Study Mar. Intrexon XON Q4 Loss Wider than Expected, Revenues Lag Mar. Nektar Therapeutics NKTR Loss Wider than Expected in Q4 Mar. Merrimack MACK Q4 Loss Lower than Expected, Revenues Top Mar. The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug May.

ET on PR Newswire - PRF. Sunesis Pharmaceuticals Reports First Quarter Financial Results and Recent Highlights Sunesis Pharmaceuticals Reports First Quarter Financial Results and Recent Highlights May.

ET on BusinessWire - BZX. Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin Blog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin May.

Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS at AACR Annual Meeting Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS at AACR Annual Meeting Apr.

Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference Mar. Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day List of Outstanding Issues for Marketing Authorization Application for Vosaroxin Mar.

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results and Recent Highlights Mar. Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year Financial Results and Recent Highlights Mar. Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference Mar. Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS and Vosaroxin Programs Jan.

Analyst Ratings Sell Under Hold Over Buy Number of Ratings 3 Full Ratings. Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora Jul. Benzinga's Top Downgrades Jul. MarketWatch Site Index Topics Help Feedback Newsroom Roster Media Archive Premium Products Mobile.

Dow Jones Network WSJ.

Trending Tickers Powered by AMD